| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| NF-kappa B p50 Subunit | 8 | 2020 | 42 | 3.530 |
Why?
|
| Brain Neoplasms | 15 | 2023 | 854 | 3.040 |
Why?
|
| NF-kappa B | 7 | 2021 | 469 | 2.520 |
Why?
|
| Glioma | 8 | 2019 | 321 | 2.120 |
Why?
|
| Dacarbazine | 6 | 2018 | 101 | 2.090 |
Why?
|
| Antineoplastic Agents, Alkylating | 6 | 2019 | 138 | 2.050 |
Why?
|
| Glioblastoma | 7 | 2025 | 285 | 1.970 |
Why?
|
| Hydrocephalus | 6 | 2022 | 108 | 1.320 |
Why?
|
| DNA Damage | 6 | 2019 | 392 | 1.210 |
Why?
|
| Genomic Instability | 2 | 2020 | 88 | 1.070 |
Why?
|
| Cerebrospinal Fluid Shunts | 6 | 2022 | 52 | 1.050 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2020 | 301 | 0.940 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 1346 | 0.930 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2018 | 684 | 0.780 |
Why?
|
| Cell Line, Tumor | 11 | 2025 | 2778 | 0.760 |
Why?
|
| CDC2 Protein Kinase | 1 | 2021 | 47 | 0.680 |
Why?
|
| Spinal Cord Compression | 2 | 2012 | 47 | 0.660 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2020 | 19 | 0.640 |
Why?
|
| Dura Mater | 2 | 2012 | 51 | 0.610 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2020 | 73 | 0.610 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2018 | 644 | 0.610 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2020 | 185 | 0.610 |
Why?
|
| Pituitary Neoplasms | 3 | 2025 | 74 | 0.600 |
Why?
|
| Cell Cycle | 1 | 2020 | 516 | 0.580 |
Why?
|
| Transcription Factors | 2 | 2018 | 1730 | 0.570 |
Why?
|
| Supratentorial Neoplasms | 1 | 2018 | 10 | 0.570 |
Why?
|
| Magnetite Nanoparticles | 1 | 2018 | 27 | 0.570 |
Why?
|
| Dog Diseases | 1 | 2018 | 37 | 0.560 |
Why?
|
| RNA, Long Noncoding | 1 | 2019 | 130 | 0.540 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 136 | 0.510 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2019 | 528 | 0.490 |
Why?
|
| Drug Delivery Systems | 2 | 2018 | 198 | 0.480 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 465 | 0.480 |
Why?
|
| Nanoparticles | 2 | 2018 | 197 | 0.470 |
Why?
|
| Animals | 22 | 2024 | 28891 | 0.470 |
Why?
|
| Mice | 13 | 2024 | 12537 | 0.470 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2015 | 4 | 0.460 |
Why?
|
| Humans | 47 | 2025 | 96105 | 0.450 |
Why?
|
| Binding Sites | 4 | 2021 | 1167 | 0.450 |
Why?
|
| Aging, Premature | 1 | 2014 | 6 | 0.440 |
Why?
|
| S Phase | 1 | 2015 | 64 | 0.440 |
Why?
|
| Promoter Regions, Genetic | 6 | 2021 | 996 | 0.430 |
Why?
|
| DNA Replication | 1 | 2015 | 177 | 0.420 |
Why?
|
| Haploinsufficiency | 1 | 2014 | 69 | 0.420 |
Why?
|
| Multiple Myeloma | 1 | 2018 | 354 | 0.410 |
Why?
|
| Transcription Factor RelA | 2 | 2018 | 49 | 0.410 |
Why?
|
| Brain | 6 | 2022 | 2482 | 0.400 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2025 | 61 | 0.400 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2007 | 713 | 0.390 |
Why?
|
| Hydrodynamics | 1 | 2022 | 20 | 0.390 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2012 | 23 | 0.380 |
Why?
|
| Mice, Nude | 4 | 2019 | 830 | 0.330 |
Why?
|
| Adenoma | 2 | 2025 | 260 | 0.320 |
Why?
|
| Signal Transduction | 2 | 2024 | 3581 | 0.320 |
Why?
|
| Endoscopy | 3 | 2004 | 374 | 0.320 |
Why?
|
| Convection | 3 | 2018 | 11 | 0.310 |
Why?
|
| Antineoplastic Agents | 3 | 2025 | 2418 | 0.310 |
Why?
|
| Aging | 1 | 2014 | 766 | 0.310 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1753 | 0.310 |
Why?
|
| DNA Methylation | 2 | 2023 | 703 | 0.290 |
Why?
|
| Genetic Therapy | 4 | 2019 | 382 | 0.280 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2008 | 186 | 0.280 |
Why?
|
| Eyebrows | 1 | 2008 | 10 | 0.280 |
Why?
|
| Epidural Abscess | 1 | 2008 | 5 | 0.280 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2007 | 18 | 0.270 |
Why?
|
| Sacrum | 1 | 2008 | 84 | 0.270 |
Why?
|
| Orbit | 1 | 2008 | 38 | 0.270 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2007 | 25 | 0.270 |
Why?
|
| Alkylation | 2 | 2020 | 32 | 0.270 |
Why?
|
| Craniotomy | 1 | 2008 | 97 | 0.260 |
Why?
|
| Phosphorylation | 3 | 2015 | 1157 | 0.260 |
Why?
|
| Spinal Neoplasms | 1 | 2008 | 131 | 0.260 |
Why?
|
| Adenoviridae | 2 | 2007 | 342 | 0.260 |
Why?
|
| Gene Transfer Techniques | 1 | 2007 | 156 | 0.260 |
Why?
|
| Serine | 2 | 2020 | 108 | 0.250 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 3157 | 0.250 |
Why?
|
| Craniopharyngioma | 1 | 2006 | 13 | 0.250 |
Why?
|
| Guanine | 1 | 2007 | 207 | 0.250 |
Why?
|
| Wilms Tumor | 1 | 2006 | 37 | 0.250 |
Why?
|
| Male | 18 | 2025 | 45863 | 0.250 |
Why?
|
| Cisterna Magna | 2 | 2022 | 11 | 0.240 |
Why?
|
| Intracranial Pressure | 2 | 2022 | 90 | 0.240 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2006 | 81 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 3489 | 0.230 |
Why?
|
| Lumbar Vertebrae | 1 | 2008 | 363 | 0.220 |
Why?
|
| Ventriculostomy | 2 | 2004 | 30 | 0.220 |
Why?
|
| Staphylococcal Infections | 1 | 2008 | 289 | 0.220 |
Why?
|
| Fibroblasts | 2 | 2020 | 777 | 0.220 |
Why?
|
| Polymers | 2 | 2018 | 220 | 0.220 |
Why?
|
| Base Sequence | 2 | 2021 | 2344 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2022 | 3639 | 0.220 |
Why?
|
| Drug Design | 1 | 2025 | 133 | 0.210 |
Why?
|
| STAT1 Transcription Factor | 1 | 2024 | 58 | 0.210 |
Why?
|
| Pinealoma | 1 | 2004 | 6 | 0.210 |
Why?
|
| Pineal Gland | 1 | 2004 | 16 | 0.210 |
Why?
|
| Proteolysis | 1 | 2025 | 124 | 0.210 |
Why?
|
| Sella Turcica | 2 | 2019 | 17 | 0.210 |
Why?
|
| Cellular Senescence | 2 | 2015 | 106 | 0.210 |
Why?
|
| Protein Binding | 3 | 2015 | 1560 | 0.210 |
Why?
|
| Neurosurgical Procedures | 3 | 2022 | 356 | 0.210 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2024 | 82 | 0.200 |
Why?
|
| Neurosurgery | 1 | 2005 | 143 | 0.200 |
Why?
|
| Animals, Newborn | 1 | 2024 | 535 | 0.200 |
Why?
|
| Mice, Knockout | 3 | 2024 | 2161 | 0.190 |
Why?
|
| Cell Death | 2 | 2014 | 264 | 0.180 |
Why?
|
| Female | 15 | 2025 | 50028 | 0.180 |
Why?
|
| Otolaryngology | 1 | 2022 | 56 | 0.180 |
Why?
|
| Treatment Outcome | 8 | 2021 | 9175 | 0.180 |
Why?
|
| Ambulatory Care Facilities | 1 | 2022 | 118 | 0.170 |
Why?
|
| Patient Satisfaction | 2 | 2022 | 514 | 0.170 |
Why?
|
| Luciferases | 2 | 2015 | 130 | 0.170 |
Why?
|
| Time Factors | 7 | 2021 | 5580 | 0.170 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 491 | 0.170 |
Why?
|
| Intracranial Thrombosis | 1 | 2001 | 31 | 0.170 |
Why?
|
| Kidney Neoplasms | 1 | 2006 | 558 | 0.170 |
Why?
|
| Survival Analysis | 2 | 2018 | 1546 | 0.160 |
Why?
|
| Ubiquitination | 1 | 2020 | 81 | 0.160 |
Why?
|
| DNA Probes | 1 | 2020 | 77 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 491 | 0.160 |
Why?
|
| Prognosis | 3 | 2025 | 4028 | 0.160 |
Why?
|
| Protein Domains | 1 | 2020 | 164 | 0.160 |
Why?
|
| Drug Therapy | 1 | 2020 | 70 | 0.160 |
Why?
|
| Subarachnoid Hemorrhage | 4 | 2001 | 154 | 0.160 |
Why?
|
| Intestinal Mucosa | 1 | 2024 | 825 | 0.150 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2001 | 181 | 0.150 |
Why?
|
| Cerebral Ventricles | 1 | 1999 | 76 | 0.150 |
Why?
|
| Transcription, Genetic | 3 | 2012 | 1192 | 0.150 |
Why?
|
| Optic Chiasm | 1 | 2019 | 16 | 0.150 |
Why?
|
| Lysine | 1 | 2020 | 190 | 0.150 |
Why?
|
| Radiography | 2 | 2013 | 826 | 0.150 |
Why?
|
| Fibrinolytic Agents | 1 | 2001 | 240 | 0.150 |
Why?
|
| Paraganglioma | 1 | 2019 | 16 | 0.150 |
Why?
|
| DNA | 3 | 2014 | 1333 | 0.150 |
Why?
|
| Interleukin-12 | 1 | 2019 | 116 | 0.150 |
Why?
|
| Thrombolytic Therapy | 1 | 2021 | 261 | 0.150 |
Why?
|
| Carbonic Anhydrase II | 1 | 2018 | 4 | 0.140 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 256 | 0.140 |
Why?
|
| Astrocytoma | 1 | 2018 | 89 | 0.140 |
Why?
|
| Telemedicine | 1 | 2021 | 229 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 98 | 0.140 |
Why?
|
| Cerebral Hemorrhage | 1 | 2021 | 374 | 0.140 |
Why?
|
| Vasospasm, Intracranial | 4 | 2001 | 36 | 0.140 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 416 | 0.140 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 106 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2024 | 590 | 0.130 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 162 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 2642 | 0.130 |
Why?
|
| Dogs | 1 | 2018 | 719 | 0.130 |
Why?
|
| Protein Multimerization | 1 | 2018 | 196 | 0.130 |
Why?
|
| Tumor Burden | 1 | 2018 | 322 | 0.130 |
Why?
|
| Neuroblastoma | 1 | 2020 | 400 | 0.130 |
Why?
|
| Child | 6 | 2022 | 7625 | 0.120 |
Why?
|
| Radiation, Ionizing | 2 | 2014 | 124 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 901 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1010 | 0.120 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 10c | 1 | 2015 | 3 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2018 | 938 | 0.110 |
Why?
|
| GPI-Linked Proteins | 1 | 2015 | 55 | 0.110 |
Why?
|
| Comet Assay | 1 | 2015 | 8 | 0.110 |
Why?
|
| Middle Aged | 6 | 2025 | 28368 | 0.110 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2015 | 75 | 0.110 |
Why?
|
| Gliosis | 1 | 2014 | 32 | 0.110 |
Why?
|
| Disease Management | 1 | 2017 | 360 | 0.110 |
Why?
|
| Kyphosis | 1 | 2014 | 26 | 0.110 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 139 | 0.110 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2015 | 64 | 0.110 |
Why?
|
| Rats | 2 | 2013 | 4155 | 0.110 |
Why?
|
| Longevity | 1 | 2014 | 60 | 0.110 |
Why?
|
| Immunoblotting | 1 | 2015 | 280 | 0.110 |
Why?
|
| Apoptosis | 2 | 2014 | 1756 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2007 | 1773 | 0.100 |
Why?
|
| DNA Primers | 1 | 2015 | 548 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 303 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 299 | 0.100 |
Why?
|
| RNA Interference | 1 | 2015 | 385 | 0.100 |
Why?
|
| Pseudotumor Cerebri | 2 | 2004 | 17 | 0.100 |
Why?
|
| Heterozygote | 1 | 2014 | 382 | 0.100 |
Why?
|
| Adult | 9 | 2025 | 28721 | 0.100 |
Why?
|
| Bone and Bones | 1 | 2014 | 280 | 0.100 |
Why?
|
| Ferric Compounds | 1 | 2013 | 41 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 897 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2014 | 526 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2021 | 2777 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 1049 | 0.100 |
Why?
|
| Nucleotides | 1 | 2012 | 99 | 0.090 |
Why?
|
| Equipment Failure | 3 | 2022 | 128 | 0.090 |
Why?
|
| Histones | 1 | 2014 | 363 | 0.090 |
Why?
|
| Skull Base | 2 | 2022 | 52 | 0.090 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1667 | 0.090 |
Why?
|
| Gene Expression | 1 | 2015 | 1320 | 0.080 |
Why?
|
| Brain Diseases | 2 | 2004 | 192 | 0.080 |
Why?
|
| Cerebral Angiography | 5 | 2001 | 217 | 0.080 |
Why?
|
| Hematoma | 2 | 2001 | 109 | 0.080 |
Why?
|
| Genotype | 1 | 2014 | 1881 | 0.080 |
Why?
|
| Age Factors | 1 | 2014 | 1963 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2014 | 2090 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2939 | 0.080 |
Why?
|
| Aged | 6 | 2025 | 20968 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2025 | 1010 | 0.080 |
Why?
|
| Infant | 4 | 2007 | 3363 | 0.070 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 2061 | 0.070 |
Why?
|
| Inflammation | 1 | 2014 | 1063 | 0.070 |
Why?
|
| Cranial Fossa, Anterior | 1 | 2008 | 4 | 0.070 |
Why?
|
| Cell Line | 1 | 2012 | 2537 | 0.070 |
Why?
|
| Pneumocephalus | 1 | 2008 | 12 | 0.070 |
Why?
|
| Frontal Sinus | 1 | 2008 | 7 | 0.070 |
Why?
|
| Phenotype | 1 | 2014 | 2578 | 0.070 |
Why?
|
| Subcellular Fractions | 1 | 2007 | 95 | 0.070 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2007 | 133 | 0.070 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2007 | 80 | 0.070 |
Why?
|
| Parietal Bone | 1 | 2007 | 17 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2007 | 394 | 0.060 |
Why?
|
| Drainage | 1 | 2008 | 172 | 0.060 |
Why?
|
| Neoplasm Transplantation | 1 | 2007 | 411 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2004 | 3974 | 0.060 |
Why?
|
| Craniosynostoses | 1 | 2007 | 73 | 0.060 |
Why?
|
| Frontal Lobe | 1 | 2006 | 131 | 0.060 |
Why?
|
| Fracture Fixation, Internal | 1 | 2007 | 90 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2007 | 445 | 0.060 |
Why?
|
| Expert Testimony | 1 | 2005 | 34 | 0.060 |
Why?
|
| Parietal Lobe | 1 | 2006 | 118 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2006 | 315 | 0.060 |
Why?
|
| Sinusitis | 1 | 2008 | 223 | 0.060 |
Why?
|
| Hospitals, High-Volume | 1 | 2025 | 42 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2007 | 1179 | 0.060 |
Why?
|
| Adenoviruses, Human | 1 | 2004 | 41 | 0.050 |
Why?
|
| Monitoring, Ambulatory | 1 | 2004 | 33 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2025 | 112 | 0.050 |
Why?
|
| Telemetry | 1 | 2004 | 36 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2025 | 10287 | 0.050 |
Why?
|
| Central Nervous System Cysts | 1 | 2004 | 10 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2025 | 436 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 3927 | 0.050 |
Why?
|
| Cerebral Arteries | 2 | 2001 | 76 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 2039 | 0.050 |
Why?
|
| Stroke | 1 | 2022 | 1087 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2025 | 640 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2007 | 2534 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2024 | 396 | 0.050 |
Why?
|
| Tryptophan | 1 | 2022 | 105 | 0.050 |
Why?
|
| Cell Survival | 1 | 2004 | 1030 | 0.050 |
Why?
|
| Office Visits | 1 | 2021 | 52 | 0.040 |
Why?
|
| Membranes, Artificial | 1 | 2001 | 38 | 0.040 |
Why?
|
| Macaca fascicularis | 4 | 2001 | 112 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2021 | 178 | 0.040 |
Why?
|
| Adolescent | 3 | 2004 | 9895 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2001 | 423 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2024 | 705 | 0.040 |
Why?
|
| Ferritins | 1 | 2000 | 31 | 0.040 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2000 | 45 | 0.040 |
Why?
|
| Biopsy | 1 | 2004 | 1220 | 0.040 |
Why?
|
| Neoplasms | 2 | 2006 | 3248 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2007 | 2480 | 0.040 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2019 | 12 | 0.040 |
Why?
|
| Cysts | 1 | 1999 | 104 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 7229 | 0.040 |
Why?
|
| Thrombosis | 1 | 2001 | 326 | 0.040 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 472 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2001 | 340 | 0.030 |
Why?
|
| Quality of Life | 1 | 2006 | 1816 | 0.030 |
Why?
|
| Disease Progression | 2 | 2018 | 1562 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 294 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2019 | 351 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2019 | 467 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 398 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 883 | 0.030 |
Why?
|
| Reoperation | 1 | 1999 | 707 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 1805 | 0.030 |
Why?
|
| Early Growth Response Protein 1 | 2 | 2006 | 58 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 656 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1619 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 1471 | 0.020 |
Why?
|
| United States | 1 | 2025 | 7768 | 0.020 |
Why?
|
| Mutation | 1 | 2023 | 4374 | 0.020 |
Why?
|
| Prospective Studies | 1 | 1999 | 4671 | 0.020 |
Why?
|
| Hemoglobins | 2 | 2001 | 196 | 0.020 |
Why?
|
| Bone Wires | 1 | 2007 | 13 | 0.020 |
Why?
|
| Genes, MDR | 1 | 2005 | 7 | 0.010 |
Why?
|
| Tumor Necrosis Factors | 1 | 2005 | 14 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2006 | 446 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 564 | 0.010 |
Why?
|
| Length of Stay | 1 | 2007 | 833 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 2002 | 20 | 0.010 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2002 | 28 | 0.010 |
Why?
|
| Lumbosacral Region | 1 | 2002 | 59 | 0.010 |
Why?
|
| Subarachnoid Space | 1 | 2001 | 18 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 2001 | 54 | 0.010 |
Why?
|
| Basilar Artery | 1 | 2001 | 40 | 0.010 |
Why?
|
| Middle Cerebral Artery | 1 | 2001 | 22 | 0.010 |
Why?
|
| Potassium Chloride | 1 | 2001 | 88 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 2001 | 93 | 0.010 |
Why?
|
| Vascular Patency | 1 | 2001 | 127 | 0.010 |
Why?
|
| Syndrome | 1 | 2002 | 453 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2001 | 333 | 0.010 |
Why?
|
| Heme Oxygenase-1 | 1 | 2000 | 22 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2000 | 297 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2001 | 1010 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2001 | 908 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 1809 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2004 | 2614 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2004 | 2591 | 0.010 |
Why?
|